The company has entered into an accelerated share repurchase program with the bank to buy back a portion of its common stock.
The BD business, which has annual revenues of about $100 million, offers technical services as well as peptones for cell culture media used in biopharmaceutical applications.
Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.
The repurchase is part of a commitment announced by the company in July 2016 to return $300 million to shareholders by the end of 2017.
Qiagen plans to return about $250 million to shareholders through a program that combines a direct capital repayment with a reverse stock split.
Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.
As of the end of its fiscal third quarter of 2016, Myriad had repurchased more than $1.1 billion of stock since the inception of the buyback program in 2010.
Under the repurchase plan, Thermo Fisher is cleared to buy $1 billion of its common stock in both the open market and through negotiated transactions.
The program will run for two years, and Bruker said that it will repurchase its common stock from time to time in amounts and at prices that it deems appropriate.
The firm also completed the repurchase of $96 million in common shares under a previous share repurchase program.
Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.
Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.
Japan is to release rules governing some gene-edited food, according to NHK World.
In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.